NY-ESTÉE-LAUDER
16.11.2021 13:02:57 CET | Business Wire | Press release
Today, The Estée Lauder Companies (NYSE:EL) (“ELC”) announced that Chris Good, Group President, North America, after nearly 25 years with the company, has made the decision to retire effective June 30, 2022. The successor to Chris’ role will be announced shortly, and Chris will partner closely with this individual to support a smooth and successful transition.
“Chris is a visionary, global leader who is deeply admired at ELC and recognized across the beauty industry worldwide. With his extensive international background, Chris’ leadership agility and deep insights into our diverse markets and consumers around the world have made an indelible impact on our business,” said Fabrizio Freda, President and Chief Executive Officer . “Known for his extraordinary business acumen, ability to build high-performing teams, and his track record of achieving strong results in both nascent and established markets globally, Chris has exemplified a commitment to excellence.”
For the past five years, Chris led ELC’s North America business, a highly complex, competitive, and fast-evolving prestige beauty landscape. He oversaw the region’s pivotal retail and organizational transformation, establishing critical capabilities to drive growth and operational efficiencies.
Additionally, Chris elevated data analytics and insights to unlock new and granular opportunities across brands, consumers, and channels. His expertise in channel strategy has accelerated the online business and strengthened the region’s retail relationships, optimizing brick-and-mortar by prioritizing high-performing doors and specialty-multi, and driving brand-building distribution in freestanding stores and emerging channels through modernized omni-experiences.
Chris consistently transformed the business while running it – pivoting with agility and resilience to accelerate recovery in a dynamic environment, while navigating numerous headwinds in North America. Over the past year and a half, he collaborated with his leadership team to steer the region through the complexities of the COVID-19 pandemic, as well as broader macro and social issues, leading with the company’s values and the wellbeing of ELC’s people in mind.
Under Chris’ steady leadership, the North American business returned to growth in fiscal year 2021 and has continued its momentum into the first quarter of fiscal year 2022. To start the new fiscal year, North America delivered strong net sales growth with sales increases across every category. Chris and his leadership team have laid a healthy foundation for long-term, sustainable recovery and growth in North America.
Chris started at ELC in Clinique Marketing in the U.K. and Ireland in 1987. After a period away from the company, where Chris took on senior marketing executive and general management roles for Unilever across Europe, North America and Asia/Pacific, he returned in 2000, as General Manager/Regional Vice President for Clinique, Asia/Pacific, where he helped grow the China and Japan affiliates in their early days. In 2005, he was named General Manager of the recently-established Russian affiliate and in 2008, he became Senior Vice President, Central and Eastern Europe, Middle East, India, and Africa.
Chris was appointed Managing Director, U.K. and Ireland in 2012. While there, he helped pioneer the company’s successful evolution from a traditional department store model into a diversified omnichannel business, leading in brand-building channels such as e/m-commerce and specialty-multi. He was promoted to President, U.K. and Ireland in 2014, and during his tenure, the business generated consistent double-digit, compound annual sales growth and tripled online net sales.
“We are grateful for Chris’ tremendous contributions to our business, and the resolve and dedication he has demonstrated to push boundaries, invent the unexpected and bring the best to ELC and beyond. He has championed our company values and embodied our culture both in the Field and alongside his teams, continuously fueling collaboration and creativity,” said William P. Lauder, Executive Chairman . “Across our global ELC family and the wider industry, Chris has nurtured strong relationships and his hospitable nature, dynamic leadership, and deep retail expertise will be truly missed. On behalf of the company and the Lauder family, I would like to wish Chris the very best in his well-deserved retirement.”
About The Estée Lauder Companies Inc.
The Estée Lauder Companies Inc. is one of the world’s leading manufacturers, marketers and sellers of quality skin care, makeup, fragrance and hair care products. The Company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, Tommy Hilfiger, M·A·C, La Mer, Bobbi Brown, Donna Karan New York, DKNY, Aveda, Jo Malone London, Bumble and bumble, Michael Kors, Darphin Paris, TOM FORD BEAUTY, Smashbox, Ermenegildo Zegna, AERIN, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, Too Faced, Dr.Jart+, and the DECIEM family of brands, including The Ordinary and NIOD.
ELC-C
ELC-L
View source version on businesswire.com: https://www.businesswire.com/news/home/20211116005443/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Curatis: Double-Digit Revenue Growth in 2025 and Major Milestones for Corticorelin Achieved24.3.2026 07:00:00 CET | Press release
Curatis Holding AG (SIX:CURN, “Curatis”) reports business revenues of CHF 10.8m (+57%) for 2025. Curatis AG increased sales in its distribution business organically by 13%, from CHF 9.5m to CHF 10.8m. The net result improved from a loss of CHF 4.3m in 2024 to a loss of CHF 1.4m in 2025. Further key statements In September 2025, our development plan for corticorelin was validated at a meeting with the FDA, enabling Curatis to proceed toward a regulatory submission supporting a pivotal study in patients suffering from peritumoral brain edema (PTBE). In November 2025, Curatis raised CHF 1.2m to progress corticorelin. The cash position as of year end 2025 was comfortable, standing at CHF 1.9m. Recently, Curatis announced a license agreement for corticorelin for Japan with significant milestone payments. Business development and finances In 2025, product sales amounted to CHF 10.3m, while service revenue amounted to CHF 0.5m. On a full year basis, Curatis AG increased revenues in its distri
AAD 2026: Galderma Showcases Latest Evidence Supporting Its Full-Spectrum, Science-Driven Solutions for Diverse Skin Needs24.3.2026 07:00:00 CET | Press release
From its Therapeutic Dermatology portfolio, Galderma will present data on the efficacy and safety of Nemluvio® (nemolizumab) in different patient populations with moderate-to-severe atopic dermatitis, including late-breaking data in pediatric patients, and share four posters on AKLIEF® (trifarotene)1-8 Additional presentations related to Dermatological Skincare will explore how artificial intelligence can identify high-risk factors for sensitive skin and Cetaphil® in different skin types9 Data from Galderma’s Injectable Aesthetics portfolio will also show how its hyaluronic acid injectables, Restylane®, and neuromodulator, RelabotulinumtoxinA*, may address aesthetic needs across the face and décolletage10-14 A total of 22 presentations will reinforce the value of Galderma’s broad and comprehensive portfolio in meeting varied patient needs across Therapeutic Dermatology, Injectable Aesthetics and Dermatological Skincare Galderma (SIX: GALD), the pure-play dermatology category leader, wi
Avanzanite Expands French Operations and Appoints Constance Sabbagh as General Manager24.3.2026 07:00:00 CET | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced its expansion into France, Europe’s second largest economy, and the appointment of Constance Sabbagh as General Manager, France. Following a €32 million Series A investment by MVM Partners announced in November 2025, Avanzanite is scaling its European infrastructure into a single, integrated platform across 32 countries – designed to bring rare disease medicines to patients in every European market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323639110/en/ Constance Sabbagh, General Manager, France “France is essential to Avanzanite’s European vision,” said Adam Plich, Co-founder and CEO of Avanzanite. “With its leadership in rare disease policy through its National Rare Disease Plans, care networks and scientific innovation, France is one of the most significant healthcare
HJS Foundation Releases JEP Protocol & HJS Framework: The "Black Box" for AI, Enabling Verifiable Human Oversight24.3.2026 04:36:00 CET | Press release
HJS Foundation (Human Judgment Systems Foundation) today released two complementary solutions: the Judgment Event Protocol (JEP) and the Human Judgment Structure (HJS) framework. As a minimalist open standard, JEP generates tamper-proof records of AI decision accountability, just like an aircraft black box; HJS embeds human judgment logic into AI operation processes — together, they transform "human oversight" from a regulatory requirement into a verifiable technical fact, providing an optional technical solution for AI accountability. How to prove that AI decisions (such as loan approvals, medical diagnoses, border screenings, etc.) have undergone human review? JEP generates immutable audit trails of human intervention through four cryptographic primitives — Judge, Verify, Delegate, Terminate; HJS builds a controllable and accountable system to prevent risks such as AI drift and ensure that human judgment guides AI operations. Current systems rely on alterable post-hoc documentation,
Power Integrations Extends Flyback Topology to Enable 440 W, Offering Simpler Alternatives to Resonant Power Designs23.3.2026 22:45:00 CET | Press release
New TOPSwitchGaN ICs more than double power output, reducing system cost, complexity, and design time APEC 2026 – Power Integrations (NASDAQ: POWI), the leader in high-voltage integrated circuits for energy-efficient power conversion, today introduced a breakthrough in flyback topology extending the power range of flyback converters to 440 W—well beyond the limits that traditionally required more complex resonant and LLC topologies. The new TOPSwitchGaN™ flyback IC family unites the company’s groundbreaking PowiGaN™ technology with its iconic TOPSwitch™ IC architecture, reducing complexity, eliminating heat sinks in many cases, shortening design time, improving manufacturability, and lowering total system cost. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323686299/en/ The new TOPSwitchGaN™ flyback IC family extends the power range of flyback converters to 440 W—well beyond the limits that traditionally required more co
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
